Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 241

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency

Open access
Doria-Rose, Nicole A., Bhiman, Jinal N., Roark, Ryan S., Schramm, Chaim A., Gorman, Jason, Chuang, Gwo-Yu, Pancera, Marie, Cale, Evan M., Ernandes, Michael J., Louder, Mark K., Asokan, Mangaiarkarasi, Bailer, Robert T., Druz, Aliaksandr, Fraschilla, Isabella R., Garrett, Nigel J., Jarosinski, Marissa, Lynch, Rebecca M., McKee, Krisha, O'Dell, Sijy, Pegu, Amarendra, Schmidt, Stephen D., Staupe, Ryan P., Sutton, Matthew S., Wang, Keyun, Wibmer, Constantinos Kurt, Haynes, Barton F., Abdool-Karim, Salim, Shapiro, Lawrence, Kwong, Peter D., Moore, Penny L., Morris, Lynn, Mascola, John R.·2016·Journal of Virology

Abstract

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable templates for vaccine design, and studies of the immunological development of these antibodies are providing insights for vaccination strategies. In addition, the most potent and broadly reactive of these bNAbs have potential for clinical use. We previously described a family of 12 V1V2-directed neutralizing antibodies, CAP256-VRC26, isolated from an HIV-1 clade C-infected donor at years 1, 2, and 4 of infection (N. A. Doria-Rose et al., Nature 509:55–62, 2014,http://dx.doi.org/10.1038/nature13036). Here, we report on the isolation and characterization of new members of the family mostly obtained at time points of peak serum neutralization breadth and potency. Thirteen antibodies were isolated from B cell culture, and eight were isolated using trimeric envelope probes for differential single B cell sorting. One of the new antibodies displayed a 10-fold greater neutralization potency than previously published lineage members. This antibody, CAP256-VRC26.25, neutralized 57% of diverse clade viral isolates and 70% of clade C isolates with remarkable potency. Among the viruses neutralized, the median 50% inhibitory concentration was 0.001 μg/ml. All 33 lineage members targeted a quaternary epitope focused on V2. While all known bNAbs targeting the V1V2 region interact with the N160 glycan, the CAP256-VRC26 antibodies showed an inverse correlation of neutralization potency with dependence on this glycan. Overall, our results highlight the ongoing evolution within a single antibody lineage and describe more potent and broadly neutralizing members with potential clinical utility, particularly in areas where clade C is prevalent. IMPORTANCE Studies of HIV-1 broadly neutralizing antibodies (bNAbs) provide valuable information for vaccine design, and the most potent and broadly reactive of these bNAbs have potential for clinical use. We previously described a family of V1V2-directed neutralizing antibodies from an HIV-1 clade C-infected donor. Here, we report on the isolation and characterization of new members of the family mostly obtained at time points of peak serum neutralization breadth and potency. One of the new antibodies, CAP256-VRC26.25, displayed a 10-fold greater neutralization potency than previously described lineage members. It neutralized 57% of diverse clade viral isolates and 70% of clade C isolates with remarkable potency: the median 50% inhibitory concentration was 0.001 μg/ml. Our results highlight the ongoing evolution within a single antibody lineage and describe more potent and broadly neutralizing members with potential clinical utility, particularly in areas where clade C is prevalent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/jvi.01791-15

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 241

Metadata

Authors
Doria-Rose, N. A., Bhiman, J. N., Roark, R. S., Schramm, C. A., Gorman, J., Chuang, G.-Y., Pancera, M., Cale, E. M., Ernandes, M. J., Louder, M. K., Asokan, M., Bailer, R. T., Druz, A., Fraschilla, I. R., Garrett, N. J., Jarosinski, M., Lynch, R. M., McKee, K., O'Dell, S., Pegu, A., Schmidt, S. D., Staupe, R. P., Sutton, M. S., Wang, K., Wibmer, C. K., Haynes, B. F., Abdool-Karim, S., Shapiro, L., Kwong, P. D., Moore, P. L., Morris, L., & Mascola, J. R.
Venue
Journal of Virology
Published
2016-01
Volume
90
Issue
1
Pages
76-91
ISSN
  • 0022-538X (ISSN-L)
  • 1098-5514
OpenAlex
W2294858472
Cited by
241
References
3
FWCI
11.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. https://app.cochat.ai/papers/10.1128/jvi.01791-15
The paper
Doria-Rose, N. A., Bhiman, J. N., Roark, R. S., Schramm, C. A., Gorman, J., Chuang, G.-Y., Pancera, M., Cale, E. M., Ernandes, M. J., Louder, M. K., Asokan, M., Bailer, R. T., Druz, A., Fraschilla, I. R., Garrett, N. J., Jarosinski, M., Lynch, R. M., McKee, K., O'Dell, S., . . . Mascola, J. R. (2016). New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. Journal of Virology. https://doi.org/10.1128/jvi.01791-15

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.